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Title: The Effects of Pulmonary Hypertension in Diabetic Zucker Rats on Pulmonary 
Vascular Contraction and Right Ventricular Size. 
Literature Review 
Introduction 
Pulmonary hypertension is a life-threatening disease that is identified by a resting 
mean pulmonary arterial pressure over 25 mmHg and established by right heart 
catheterization (Saglam et al., 2015). The symptoms commonly associated with 
pulmonary hypertension include fatigue, dyspnea, syncope, and chest pain, which 
severely limit quality of life in diagnosed patients (Saglam et al., 2015). According to 
recent studies in patients with pulmonary hypertension, the one, three and five year 
mortality rates are 8%, 25%, and 34%, respectively (Burudpakdee, Shah, Joish, Divers, & 
Yaldo, 2014). Although some advances have been made in therapies for pulmonary 
hypertension, the prognosis is still poor, and there is a lack of understanding of its 
mechanisms (Voelkel, Gomez-Arroyo, Abbate, Bogaard, & Nicolls, 2012). This study 
aims to examine and understand some of those mechanisms in the Zucker Rat. 
Additionally, previous analyses have shown that individuals with diabetes 
mellitus have an increased incidence of pulmonary hypertension (Gurney, & Howarth, 
2009). The number of individuals with diabetes has skyrocketed in previous years, and 
the International Diabetes Federation shows that the worldwide prevalence of diabetes as 
of 2013 is 382 million (Shi, & Hu, 2014). Additionally, this number is expected to rise 
and could be as high as 592 million by 2035 (Shi, & Hu, 2014). Dynamics that could 
bring about pulmonary hypertension associated with diabetes include microvascular 
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disease, autonomic neuropathy, and metabolic derangements such as hyperglycemia and 
dyslipidemia (Blendea, McFarlane, Isenovic, Gick, & Sowers, 2003). The mechanisms of 
these dynamics are poorly understood, and the relationship between pulmonary 
hypertension and diabetes should be examined. The purpose of this study was to examine 
the difference in effect of diabetes on pulmonary hypertension using an animal model. 
Pulmonary Hypertension 
 Pulmonary hypertension (PH) is a dynamic disease distinguished by the 
uncontrolled growth of smooth muscle and pulmonary vascular endothelial cells causing 
constriction of the pulmonary arteries which results in abnormally high vascular 
resistance and failure of the right heart characterized by right ventricular hypertrophy 
(Moral-Sanz et al., 2011). Right ventricular hypertrophy eventually causes heart cells to 
die, which has been demonstrated to be a crucial event during the end stages of heart 
failure (Doggrell, & Brown, 1998). A number of possible causes of PH have been 
identified, but the mechanisms of the disease are complicated and poorly understood 
(Brunner et al., 2014). Although progress has been made in the management of PH, the 
prognosis is still poor, and there is currently no curative treatment for this destructive 
disease (West et al., 2014; Farkas, & Kolb, 2013). Current vasodilator treatments act to 
increase circulation in the lungs and help to stave off increased pulmonary vascular 
pressures resulting in right ventricular hypertrophy. However, this does not target the 
underlying problem of the disease, which is pulmonary vascular remodeling (Farkas, & 
Kolb, 2013). 
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Diabetes Mellitus Type II 
 Diabetes is a disease chiefly distinguished by high blood sugar levels that increase 
the risk of developing microvascular damage such as retinopathy, neuropathy, and 
nephropathy. According to the World Health Organization, it decreases life expectancy 
and shows appreciable morbidity due to diabetes related microvascular problems, a lesser 
quality of life, and serious macrovascular problems such as heart disease, peripheral 
vascular disease, and stroke. Diagnosis of diabetes has seen a startling increase in the past 
twenty years, and current statistics show approximately 6.4% of the world’s population 
has some form of diabetes (Carter, Gray, Troughton, Khunti, & Davies, 2010).  
 According to Movahed and colleagues (2005), the prevalence of PH in diabetic 
patients is significantly higher independent of other comorbidities such as coronary artery 
disease, hypertension, heart failure, or smoking. One of the complications of uncontrolled 
glucose levels in diabetes is the development of pulmonary hypertension (Gurney, & 
Howarth, 2009). Recent studies have also linked endothelial dysfunction as an important 
factor in the progression of diabetic retinopathy, nephropathy, and atherosclerosis in both 
types of diabetes (Lopez-Lopez et al., 2008). Despite the close relationship with systemic 
and pulmonary cardiovascular disease, it has only been shown recently that type 1 and 
type 2 diabetes are risk factors for pulmonary hypertension. Limited research has been 
conducted to examine this relationship (Lopez-Lopez et al., 2008).  
Pharmacology 
 Potassium Chloride (KCl). Potassium chloride (KCl) has been used in a number 
of studies to produce substantial contractions in mammalian cardiac muscle. It has also 
Pulmonary Hypertension 4 
 
been used to avoid G-protein coupled receptor (GPCR) activation and mobilize smooth 
muscle by altering the K+ equilibrium potential and fastening membrane potential above 
the resting level. It has been used in other studies to induce maximum contractions in 
vascular smooth muscle that can then be used as a reference for further experimentation 
(Schuh et al., 2003). Because of these substantial contractions, KCl was used in the study 
to test pulmonary arterial vascular rings for contractility (Bassett, & Wiggins, 1976).  
 Phenylephrine. Phenylephrine is a sympathomimetic vasoconstrictor similar in 
structure to epinephrine. Its chemical structure deviates from epinephrine only in the 
absence of one hydroxyl group on the benzene ring (Eccles, 2007). Phenylephrine is a 
somewhat discriminatory α1 agonist, with poor α2 agonist activity (Eccles, 2007). It 
induces contraction of muscle through various mechanisms and calcium channels such as 
L-type voltage-operated calcium channels and receptor-operated calcium channels (Kim, 
et al., 2014). Phenylephrine was used in this study to initiate pulmonary arterial vascular 
contraction. 
 Acetylcholine Acetylcholine is a neurotransmitter that plays an important role in 
many biological processes of both the central and peripheral nervous system (Pinheiro et 
al., 2015). The synthesis of acetylcholine occurs in an uncomplicated biochemical 
process. It involves the transfer of the acetyl group from acetyl-coenzyme A to choline by 
an enzyme called choline acetyltransferase (Schwarz et al., 2013). Once synthesized, 
acetylcholine is the excitatory neurotransmitter used at the synapse between the 
neuromuscular junctions in mammals (Bagnall, du Lac, & Mauk, 2013). It has also been 
documented to induce smooth muscle dilation in vivo in mammalian pulmonary arteries 
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and systemic arteries and was used in this study to induce vasodilation of pulmonary 
arterial vasculature (Vanhoutte, Rubanyi, Miller, & Houston, 1986) 
 Monocrotaline (C16H23NO6). Monocrotaline (MCT) is a toxic pyrrolizidine 
alkaloid derived from the seeds of the Crotalaria spectabillis plant.  When administered 
in small doses caused delayed and progressive lung injury resulting in pulmonary 
vascular remodeling, pulmonary hypertension and resultant right heart hypertrophy 
(Schultze & Roth, 1998; Broderick, Wang, Gutkowska, Wang, & Jankowski, 2010). 
Pulmonary hypertension produced by MCT injection is well documented in numerous 
rodent studies of pulmonary hypertension (Broderick, T. L., & King, T. M. 2008).  
Animal Models 
The utilization of the rat animal model is economically reasonable and allows for 
measurement of important hemodynamic and cardiac parameters in vitro (Doggrell, & 
Brown, 1998). The Obese Zucker rat has been used in many studies and has become a 
popular model for type II diabetes and its links to systemic vascular dysfunction (Moral-
Sanz, Moreno, Cogolludo, & Perez-Vizcaino, 2014). These Zucker rats typically develop 
obesity and insulin resistance around seven weeks of age (Schmidt, Dorsey, Beaudet, & 
Peterson, 2003; Shiota, & Printz, 2012). 
This study examined a variety of factors including right ventricular pressures and 
heart weights, right ventricular ratios, and contractility properties of the pulmonary 
vascular ring using a Schuler tissue bath. Elevation of right ventricular pressures and the 
development of right ventricular hypertrophy are clinical signs of pulmonary 
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hypertension resulting in pulmonary arterial vascular remodeling with thickening of the 
vascular wall which may impact contractile and/or relaxant ability of the vessel. 
Specific Aims 
 The aims of this study are to compare the effects of pulmonary hypertension 
between non-diabetic control Zucker rats and Zucker rats with PH and PH plus Type II 
diabetes in terms of pulmonary artery relaxation function and right ventricular 
hypertrophy. 
Hypothesis 
 The hypotheses of this study are  
1. The pulmonary arterial vascular contractile responses will be decreased in the PH 
and PH plus type II diabetic rats as compared to the control rats; and 
2. The pulmonary arterial vascular relaxant responses will be decreased in the PH 
and PH plus type II diabetic rats as compared to the control rats.    
Methodology 
This study was performed following approval of University of Arkansas-Fayetteville 
Institutional Animal Care and Use Committee (IACUC). All University and Laboratory 
Animal Training Association (LATA) protocols and guidelines for animal handling were 
followed. 
Sample  
 An a priori power analysis was conducted to establish group sizes of 8 were 
sufficient to achieve a power value of >.80. A three-group experimental design was used. 
Pulmonary Hypertension 7 
 
The groups consisted of age-matched Zucker rats including 9 control Zucker rats, 6 lean 
PH Zucker (Fa/fa) rats and 4 type II diabetic PH Zucker (fa/fa) rats(Harlan Laboratories, 
Indianapolis, IN). The study experienced a 50% death rate (n=4) in the lean Zucker 
(Fa/fa) rats and 1 death in the type II diabetic Zucker (fa/fa) group prior to the 
experiment. Additionally the study experienced 1 type II diabetic Zucker (fa/fa) 
pulmonary artery tissue death during the experiment accounting for the variable number 
of rats in each group.  
Animal Care 
 Animals were received into the Central Live Animal Facility (CLAF) facility and 
allowed to acclimate to their surroundings for two weeks. Animals were housed two rats 
per cage (10.25”W X 19”D X 8”H) with micro-filter tops and autoclaved pine litter. The 
animals were allowed standard rat chow food and water ad libitum. A reversed 12:12 
light-dark cycle was used and the rats were allowed unrestricted cage activity. All 
procedures were performed under a laminar hood in the CLAF facility until the terminal 
phase of the experiment. At that time, animals were transported to Dr. Smith-Blair’s 
laboratory in HHPR 321 and allowed to acclimate for a minimum of 1 hour prior to the 
beginning of the experiment. 
Pre-Experiment Protocol 
Monocrotaline (MCT) Injection Procedure Following the arrival and a two 
week stabilization period in the CLAF, MCT 40 mg/kg was injected subcutaneously into 
the experimental groups of rats. This dose of MCT has been demonstrated by Handoko 
and colleagues (2009) to produce stable pulmonary hypertension with a preserved cardiac 
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output. The animals were observed daily for four weeks for clinical signs of complicating 
right heart failure and compromised cardiac output (respiratory distress, cyanosis, 
lethargy, weight loss, and decrease in responsiveness to stimulation). Five animals were 
euthanized according to the approved IACUC protocol due to progressive pulmonary 
decompensation with persistent weight loss and lethargy. 
Body Weight/Blood Glucose Body weight was measured daily and blood 
glucose levels measured weekly on all animals. Blood glucose levels were obtained using 
a micro-lancet to obtain blood from the rat tail and measured using the Accu-Check 
Active™ meter.  
General Experimental Procedures 
On the day of the terminal phase of the experiment, the animals were transported 
to the laboratory and allowed to acclimate for a minimum of 1 hour. Following obtaining 
a surgical plan of anesthesia using pentobarbital sodium (50 mg/kg body weight), a 
tracheotomy was performed and a stainless steel tracheotomy cannula with Luer adapter, 
1.8 mm OD, 25 mm in length (Harvard Apparatus, Holliston, MA) was inserted and 
sutured in place. The tracheal cannula was connected to pressure-controlled rat ventilator. 
The settings of the rodent ventilator were 10 mL/kg (tidal volume) and 60 cycles/min. 
 The diaphragm was exposed via a midline abdominal incision. A 20G needle 
attached to a low pressure transducer was inserted through the diaphragm into the right 
ventricle. Right ventricular pressure was measured via the Digi-Med™ (Model 200) low-
pressure transducer. This model of transducer measures pressures within an error range of 
+ 0.1 mmHg. 
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 Following obtaining the right ventricular pressure, the animal was given an 
overdose of pentobarbital (100 mg/kg body weight). The thorax was quickly opened 
surgically and the heart and lungs removed. The heart and lungs were submerged in a 
dissection dish containing Krebs solution bubbled with low flow 95% oxygen/5% CO2. 
Vascular Reactivity Studies The pulmonary artery rings (~2 mm long and an 
internal diameter ~ 0.3-0.5 mm) were dissected and mounted on a tissue hook supports in 
a Schuler tissue bath™ (Harvard Apparatus, Holliston, MA). After stretching to give an 
appropriate resting tension  (equivalent to 0.75 g), tissues were continuously bathed in the 
chamber with Krebs solution at 37⁰C with a mixture of 95% O2-5% CO2 as previously 
described by Cogollundo et al (2001). 
KCL contraction challenge. Following equilibration, the vascular muscle 
contractile responses were evaluated using a KCL 96mM solution infused into the tissue 
bath chamber. This procedure was performed to obtain a baseline measurement of the 
viability of each pulmonary artery vessel to ensure the artery was not damaged during 
isolation or mounting of the vessel. The KCL was allowed to saturate the vascular ring 
for 2 minutes after which the peak contraction was recorded. Following measurement, the 
vessel was thoroughly rinsed with Krebs’ solution and the vascular ring allowed for 
equilibrate for 10 minutes. This process was repeated twice. Following the experiment 
the developed force was calculated (peak contractile force – resting tension) to reflect the 
change in contractile properties of the vessel.  
 Tissue rings were then exposed to phenylephrine 10-9 to 10-4 mM concentrations 
to induce a contraction 70% of the KCl max contraction is obtained. Tissues were rinsed 
thoroughly between concentration level testing and allowed to rest 2 minutes. Once the 
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phenylephrine concentration producing 70% of the response to KCl, Phenylephrine (10-7 
mM) was used to evaluate the contractile response.    
The tissue baths were then infused with phenylephrine (10-7 mM) along with 
increasing concentrations of acetylcholine (10-9to 10-4 mM) to test the relaxant properties 
of the tissue. Concentration curves were obtained for acetylcholine concentrations (10-9to 
10-4 mM). 
Measurements obtained in this study included the following: baseline resting 
tension, peak contraction, and developed force (calculated). The optimal baseline resting 
tension was determined prior to the start of each experiment and was adjusted to be 
maintained constant throughout the experiment. The peak contraction was determined as 
the maximum force (gms) produced by the pulmonary arterial vascular ring when 
exposed to either KCL, phenylephrine or phenylephrine/acetylcholine solutions. The 
developed force was calculated as difference between the peak contraction and the 
baseline resting tension and was used as the measure of contractile change with each 
measurement. Using these measurements, the effectiveness of the various concentrations 
of phenylephrine and phenylephrine/acetylcholine was gauged.  
Results 
A one-way analysis of variance (ANOVA) was used to examine if there were 
statistically significant differences between the means of the three groups in relation to 
weight, height, blood glucose, KCl contractions, and heart weight and heart ratio. Second, 
one-way repeated measures ANOVA was used to examine if differences existed between 
groups with respect to developed force at varying concentrations of phenylephrine and 
phenylephrine/acetylcholine solutions.  
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 An initial alpha level of 0.05 was selected as the criterion for statistical 
significance. This level of significance was then adjusted to an alpha level of 0.01 using 
an adjustment in the Bonferroni procedure to control for an overall type I error rate due to 
performing multiple analyses. To account for deviations from sphericity, the Greenhouse-
Geisser Epsilon correction factor was used to adjust the univariate test degrees of 
freedom for each test involving with-in subject effects.  
Weight and Length. Three groups of rats, two groups with induced pulmonary 
hypertension (PH) and one control group, were used for these experiments and included 
control lean rats (N=9), lean PH rats (N=6) and type II diabetic PH rats (N=4). An 
ANOVA demonstrated there was a statistically significant difference between groups 
with respect to weight [F (2, 18) = 87.25, p < .005]. Post hoc tests revealed there was a 
statistically significant difference between the diabetic PH rats and the lean control rats 
(p< .005) and lean PH rats (p < .005) but there was not a statistically significant 
difference in weight between the lean PH and lean control rats (Figure 1). An ANOVA 
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Figure 1 – Comparison of mean weights (gms) between lean PH, Diabetic PH and control 
rats. No statistically significant difference was noted between Lean PH and Control rats.   
 *Denotes a significant difference between Lean PH and Diabetic PH rats. 
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Figure 2 – Comparison of the body lengths (cm) of the three groups. No statistically 
significant differences were noted between groups in relation to length 
 
Blood Glucose Levels. Blood glucose levels were monitored weekly and 
analyzed using ANOVA. A statistically significant difference in blood glucose was noted 
between groups [F (2, 18) = 243.94, p < .005].  A post hoc test revealed a statistically 
significant higher blood glucose levels in the diabetic PH than the lean PH rats (p< .005) 
and lean control rats (p <.005). There was not a statistically significant difference in 
blood glucose levels between the lean PH and lean control rats (Figure 3). 
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Figure 3 – Comparison of the mean blood glucose levels (mg/dL) of the three groups.  
* Denotes statistically significant difference between Lean PH rats and Diabetic PH rats 
and between Diabetic PH rats and Control rats. No statistically significant difference in 
blood glucose between Lean PH and Control rats.  
 
Right Mean Ventricular Pressures. An ANOVA revealed a statistically 
significant difference in the mean right ventricular pressures between the three groups [F 
(2,18) = 14.46, p < .005]. Post hoc tests revealed there was not a statistically significant 
difference between the right mean ventricular pressures in the lean PH and diabetic PH 
rats. However, the control rats had statistically significant lower right ventricular 
pressures than either the lean PH rats (p= .001) or the diabetic PH rat (p=.002) (Figure 4).  
* * 
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Figure 4 – Mean right ventricular pressures between the three groups 
* Denotes statistically significant difference in right ventricular pressure between Lean 
PH and Diabetic PH with regard to Control rats.  
 
 
Mean Heart Weight. An ANOVA determined there was a statistically significant 
difference between the three groups with regard to mean heart weight [F (2, 18) =16.86, 
p<.005]. Post hoc comparisons indicated a statistically significant increase in the lean PH 
(p=.001) and diabetic PH (p<.005) rate mean heart weights as compared to the control rat 
mean heart weights (Figure 5).   
Heart weight Ratio. Heart weight ratios were calculated by the following 
formula: (left ventricular heart weight – septum)/right ventricular weight.  An ANOVA 
was used to determine if there were statistically significant difference between the three 
groups of rats. The analysis did not demonstrate a statistically significant difference 
between the groups of rats [F (2, 18) = .34, p= .71]. 
  
* 
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Figure 5 – Mean Heart Weight comparisons between the three groups. 
*Denotes a statistically significant difference between Lean PH and Diabetic PH with 
regard to Control rats.  
 
 
Potassium Chloride Infusion. Potassium chloride (KCl) infusions (0.096 mol/L) 
were used to test the contractility of the pulmonary vascular arterial rings for viability. It 
also was used to determine the concentration of Phenylephrine HCl infusion (a 
concentration that produced 70% peak contraction generated by the KCl test) to be used 
for the experiment.  An ANOVA determined there was no statistically significant 
difference in peak contraction between the groups with the first contraction test [F (2, 17) 
= 1.96, p= .18] or the second contraction test [F (2, 17) = 3.28, p= .06] (Figure 6). 
Additionally there was not statistically significant difference in developed force between 
the groups [F (2, 14) = .63, p= .55].  
* 
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Figure 6 – Mean Peak Contraction (gms) with infusion of KCL. No statistically 
significant difference was noted between groups with either KCl test. 
 
Phenylephrine HCl Infusion. Following the KCl contraction tests, the 
magnitude of developed force produced to achieve 70% of the peak KCl contraction 
through stimulation of the pulmonary artery vascular ring was determined through 
exposure of the tissues to phenylephrine HCl concentrations of -9 mOm to -4mOm 
successively added to the tissue wells. A concentration of phenylephrine HCl -7mOm 
was used as the constant infusate for the acetylcholine phase of the experiment based on 
the peak contractions of the 3 groups (Figure 7). 
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Figure 7 – Mean peak contraction at varying levels of phenylephrine 
A one-way repeated measures ANOVA was used to determine if there was a 
statistically significant difference in developed force at phenylephrine concentrations of -
9 mOm, -8 mOm, and -7 mOm between the Control group, and the Lean PH and Diabetic 
PH groups. The assumption of sphericity was not met, as assessed by Mauchly’s test of 
sphericity, x2 (2) = 8.92, p= .01.   Epsilon (Ɛ) was .61 as calculated by Greenhouse & 
Geisser (1959), and was used to correct the one-way repeated measures ANOVA. The 
change in phenylephrine concentrations did not elicit statistically significant changes in 
developed force over time [F (1.23, 12.28) = 2.93, p = .12] (Figure 8).  
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Figure 8. Developed force of pulmonary arterial vascular contraction (gms) at varying 
levels of Phenylephrine 
 
 
Acetylcholine/phenylephrine (-7mOm) infusion. Phenylephrine HCl 
concentration (-7mOm) produced a peak contraction of 70% of the maximum contraction 
obtained with the KCL infusion was infused in the tissue bath in combination with 
acetylcholine concentrations from -9mOm to -4mOm. Following each successive 
concentration of acetylcholine pulmonary arterial vascular contractility measures were 
obtained. An ANOVA was used to determine if there were statistically significant 
differences between the Control group, and the Lean PH and Diabetic PH groups at the 
tested concentrations of phenylephrine/acetylcholine -9 mOm to -4 mOm. Mauchly’s test 
of sphericity indicated that the assumption of sphericity had been violated, x2 (9) = 38.57, 
p< .005. Therefore the Greenhouse & Geisser (1959) was calculated and used to correct 
the one-way repeated measures ANOVA.  There was no statistically significant 
difference in peak contraction [F (2.22, 33.31) = 2.32, p= .11] or developed force [F 
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(1.68, 25.14) = 2.17, p= .14] of the pulmonary arterial vascular tissue between any 
concentrations of acetylcholine (Figure 9).  
 
Figure 9. Acetylcholine/Phenylephrine Mean Peak Concentration between groups at 
varying concentrations of acetylcholine.  No statistical significant difference noted.  
 
A one-way repeated measures ANOVA was computed to compare the developed 
force by groups. Data from the acetylcholine/phenylephrine -5mOm concentration was 
deleted from the observations due to an outlier. Mauchly’s test of sphericity indicated that 
the assumption of sphericity had been violated, x2 (9) = 33.96, p< .005. Epsilon (ɛ) was 
.415 as calculated by the Greenhouse & Geisser (1959), which was used to correct the 
one-way repeated measures ANOVA.  There was no statistically significant difference in 
developed force [F (1.66, 21.59) = .964, p= .12] of the pulmonary arterial vascular tissue 
between any concentrations of phenylephrine/acetylcholine (Figure 10).  
 
Pulmonary Hypertension 21 
 
 
Figure 10 – Comparison of the Acetylcholine/Phenylephrine (-7mOm) Mean Developed 
Force (gms) between the three groups. No statistically significant differences were noted 
between groups at any of the acetylcholine concentrations.  
 
Discussion 
The body weights and lengths of the diabetic PH rats in our study were 
significantly heavier than both the Lean PH and Control rats, which is consistent with the 
literature (Moral-Sanz, et al., 2014). Additionally blood glucose levels of type II diabetic 
Zucker rats were significantly higher (mean = 189.25 mg/dl) than the lean rats (mean = 
87.0) or the control rats (mean = 87.0) confirming the development of type II diabetes.  
This development which is consistent with insulin resistance in the Zucker rats (fa/fa) is 
consistent with other studies (Schmidt, Dorsey, Beaudet, & Peterson, 2003).  
Pulmonary hypertension is characterized by elevated pulmonary pressures 
resulting in compensatory right ventricular hypertrophy. The weight of the right ventricle 
can be used as an indirect index of pulmonary artery pressure. Increased right ventricular 
Pulmonary Hypertension 22 
 
weight compared to the left ventricle plus the septum weight has been described in the 
literature as a measure of the hypertrophy (Moral-Sanz et al., 2012).  Additionally, 
increased right ventricular pressure has also been noted in PH (Csiszar et al., 2009). 
Statistically significant increases in right ventricular pressures seen in the lean PH and 
diabetic PH rats were also consistent with the literature. Our data highlights the drastic 
differences between the two experimental groups and the control group. Heart weights 
and the heart weight ratio were determined in all animals to evaluate right ventricular 
hypertrophy. The heart weights indicated that both experimental groups of rats had 
greater heart weights than the control rats suggesting that pulmonary hypertension existed 
in these groups. Hearts from rats affected with PH were hypothesized heavier than rats 
that do not have PH which was consistent with the literature (Moral-Sanz et al., 2012). 
However, we did not find an increase in heart weight ratio (left ventricular heart weight – 
septum/right ventricular weight) in the PH experimental groups which came as a surprise 
after significance was found in right ventricular pressures and heart weights. Although 
measures to maintain reproducibility of heart dissection was observed by having the same 
researcher dissecting each heart, some variation in tissue landmarks may have impacted 
this latter measurement.   
Potassium chloride was used to establish a maximum contraction of the tissues, 
confirmed viability of the tissue samples, and provided a consistent level of contraction to 
be achieved with the phenylephrine infusion. Although not statistically significant, it is 
interesting to note that the diabetic PH group had a slightly higher mean peak contraction 
in response to KCL infusion. The findings of the phenylephrine contractions correspond 
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to results found in other studies that used similar concentration-response curves for 
phenylephrine (Gomart et al., 2014).  
 It has been noted in numerous studies (Dietrich et al., 2010; Vanhoutte, Rubanyi, 
Miller, & Houston, 1986) that acetylcholine induces smooth muscle dilation in 
pulmonary arteries. We observed dose-related dilation effects and were able to compare 
the differences between lean PH rats, diabetic PH rats, and a control group with neither 
morbidity. The results of the study indicate that there were no significant differences in 
the pulmonary artery contractile function between the three groups of rats. Additionally, 
we found no statistically significant changes to the relaxant properties with increased 
concentrations of acetylcholine. Although no significance was found in pulmonary artery 
contractile function in this study, there may be alternative mechanisms that could be 
tested instead of the dilation effects of acetylcholine. One such mechanism could be the 
vasodilatory effects of nitric oxide (NO) on pulmonary artery contractile function 
(Hampl, Tristani-Firouzi, Hutsell, & Archer, 1996). Future studies should aim to test 
these alternative mechanisms.  
The identified limitations encountered during the course of the research may have 
impacted the results of the study. The laboratory experienced death of a large number of 
obese Zucker rats. Additionally, we experienced death of one of the tissues after 
extraction. Both factors limited the amount of data available to four rats in that group. 
Possible causes of death for the rats may have included complications from the MCT 
injection and the increase in severity of PH progressing to death in the animal. Although 
the dosage of MCT used (40 mg/kg) has been found to produce stable PH in other studies 
(Handoko et al., 2009) it is unclear why some animals experience a more severe disease 
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progression. The total experimental time of these experiments was longer than other 
studies, which include some ending as soon as 28 days post injection of MCT 
(Dumitrascu et al., 2008). Our longer study period could have contributed to the higher 
mortality from PH complications. Alternatively, a virus may have infected the rats and 
been spread through their respiratory tract, although preventive measures were taken with 
the micro-filter tops and autoclaved pine litter. The quick nature in loss of the animals 
lends to an infection. In future research, extra measures should be taken to ensure that 
fewer rat deaths are recorded. 
Another limitation is that we induced pulmonary hypertension artificially through 
MCT injection, and this is not the way it develops in vivo. The development of 
pulmonary hypertension in vivo could create significant deviations from the results found 
through artificially mimicking it with injection of MCT. Induction of pulmonary 
hypertension with MCT happens in a matter of weeks, whereas development in vivo 
takes much longer. During the experimental phase of the study, some variation in the 
tissue extraction may have taken place. However, this limitation was addressed during the 
experiments by having the same researcher extract all hearts for consistency. Although 
the pH of the all solutions was carefully measured prior to injection into the tissue bath, 
some change in pH may have occurred during the measurement phases of the experiment 
which could affect the viability of the arteries. Both alkalosis and acidosis have a critical 
influence on pulmonary artery viability.  
A final limitation of the study may be the size of the isolated arteries used in the 
study. The targeted tissues for dissection were the first branch of the right and left branch 
of the pulmonary artery. Large conducting arteries contribute little to pulmonary vascular 
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resistance. Resistance arteries are technically difficult to isolate and some degree of error 
may have occurred with the dissection process of these arteries.  
Future studies should aim to mimic a slower progression of PH such as hypoxia 
and determine if there are ways to conduct a study similar to this on older rats since the 
rats used in our study were young. The age of the animal can influence vascular function. 
Aging is associated with structural changes and functional response of arteries.  In 
addition, it may help to extend the time each tissue is exposed to the dosages of KCl, 
phenylephrine, and acetylcholine. When measuring the baseline for the tissues during 
experimentation, ten minute time intervals were allowed between each dose of the three 
chemicals for equilibration. Additional time may impact the measurements. 
In summary, we have shown that there were no significant differences in the 
pulmonary artery contractile function between the three groups. Additionally, pulmonary 
arterial vascular relaxant responses were not significantly decreased in the PH and PH 
plus type II diabetic rats compared to the control rats as hypothesized.  
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